Last reviewed · How we verify
Tolterodine 6
Tolterodine is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency.
Tolterodine is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.
At a glance
| Generic name | Tolterodine 6 |
|---|---|
| Also known as | Detrusitol ER 4mg |
| Sponsor | KYU-SUNG LEE |
| Drug class | Muscarinic receptor antagonist |
| Target | M2 and M3 muscarinic receptors |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Tolterodine selectively antagonizes M2 and M3 muscarinic receptors in the detrusor muscle of the bladder. By blocking these receptors, it prevents acetylcholine-induced bladder contractions, thereby increasing bladder capacity and reducing the frequency of micturition and urgency episodes associated with overactive bladder.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and frequency
Common side effects
- Dry mouth
- Headache
- Constipation
- Dizziness
- Blurred vision
Key clinical trials
- A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain (PHASE3)
- Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics (PHASE4)
- Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up. (PHASE1)
- Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients (PHASE4)
- Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms (NA)
- Behavioural Therapy With Checklist for Overactive Bladder (NA)
- Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence. (PHASE4)
- Comparison of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tolterodine 6 CI brief — competitive landscape report
- Tolterodine 6 updates RSS · CI watch RSS
- KYU-SUNG LEE portfolio CI